# A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Study · id `cardio:ct-nct06897475` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06897475](<https://clinicaltrials.gov/study/NCT06897475>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06897475

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06897475. Randomized; double masking; primary purpose treatment. Start 2025-03-28 (actual); primary completion 2027-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06897475, source copy `cardio:ctgov-nct06897475-2026-11-04`, retrieved 2026-11-18)
- Started: 2025-03-28 (actual) (ClinicalTrials.gov record NCT06897475, source copy `cardio:ctgov-nct06897475-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT06897475, source copy `cardio:ctgov-nct06897475-2026-11-04`, retrieved 2026-11-18)
- Completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06897475, source copy `cardio:ctgov-nct06897475-2026-11-04`, retrieved 2026-11-18)
- Countries: United States; Canada; Germany; Poland; Puerto Rico; United Kingdom (ClinicalTrials.gov record NCT06897475, source copy `cardio:ctgov-nct06897475-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06897475-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Condition: Type 2 Diabetes
- Intervention (Drug): LY3457263
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 1c48b51622f5a7e80c1646f285a1fe7691e22062a4401dfa48950d6923e840c1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
